Literature DB >> 26635035

von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII.

Nicoletta Sorvillo1, Robin B Hartholt2, Esther Bloem2, Magdalena Sedek2, Anja ten Brinke3, Carmen van der Zwaan2, Floris P van Alphen2, Alexander B Meijer4, Jan Voorberg5.   

Abstract

It has been proposed that von Willebrand factor might affect factor VIII immunogenicity by reducing factor VIII uptake by antigen presenting cells. Here we investigate the interaction of recombinant von Willebrand factor with immature monocyte-derived dendritic cells using flow cytometry and confocal microscopy. Surprisingly, von Willebrand factor was not internalized by immature dendritic cells, but remained bound to the cell surface. As von Willebrand factor reduces the uptake of factor VIII, we investigated the repertoire of factor VIII presented peptides when in complex with von Willebrand factor. Interestingly, factor VIII-derived peptides were still abundantly presented on major histocompatibility complex class II molecules, even though a reduction of factor VIII uptake by immature dendritic cells was observed. Inspection of peptide profiles from 5 different donors showed that different core factor VIII peptide sequences were presented upon incubation with factor VIII/von Willebrand factor complex when compared to factor VIII alone. No von Willebrand factor peptides were detected when immature dendritic cells were pulsed with different concentrations of von Willebrand factor, confirming lack of von Willebrand factor endocytosis. Several von Willebrand factor derived peptides were recovered when cells were pulsed with von Willebrand factor/factor VIII complex, suggesting that factor VIII promotes endocytosis of small amounts of von Willebrand factor by immature dendritic cells. Taken together, our results establish that von Willebrand factor is poorly internalized by immature dendritic cells. We also show that von Willebrand factor modulates the internalization and presentation of factor VIII-derived peptides on major histocompatibility complex class II. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26635035      PMCID: PMC4815722          DOI: 10.3324/haematol.2015.137067

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  39 in total

Review 1.  Cell biology of antigen processing in vitro and in vivo.

Authors:  E Sergio Trombetta; Ira Mellman
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 2.  Clearance mechanisms of von Willebrand factor and factor VIII.

Authors:  P J Lenting; C J M VAN Schooten; C V Denis
Journal:  J Thromb Haemost       Date:  2007-04-07       Impact factor: 5.824

3.  Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain.

Authors:  Eszter Herczenik; Simon D van Haren; Aleksandra Wroblewska; Paul Kaijen; Maartje van den Biggelaar; Alexander B Meijer; Luisa Martinez-Pomares; Anja ten Brinke; Jan Voorberg
Journal:  J Allergy Clin Immunol       Date:  2011-10-01       Impact factor: 10.793

4.  VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

Authors:  Suryasarathi Dasgupta; Yohann Repessé; Jagadeesh Bayry; Ana-Maria Navarrete; Bharath Wootla; Sandrine Delignat; Theano Irinopoulou; Caroline Kamaté; Jean-Marie Saint-Remy; Marc Jacquemin; Peter J Lenting; Annie Borel-Derlon; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

5.  Requirements for cellular co-trafficking of factor VIII and von Willebrand factor to Weibel-Palade bodies.

Authors:  M van den Biggelaar; R Bierings; G Storm; J Voorberg; K Mertens
Journal:  J Thromb Haemost       Date:  2007-11       Impact factor: 5.824

6.  Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells.

Authors:  Nicoletta Sorvillo; Simon D van Haren; Paul H Kaijen; Anja ten Brinke; Rob Fijnheer; Alexander B Meijer; Jan Voorberg
Journal:  Blood       Date:  2013-01-31       Impact factor: 22.113

7.  The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A.

Authors:  C L Eckhardt; J Astermark; S Q Nagelkerke; J Geissler; M W T Tanck; M Peters; K Fijnvandraat; T W Kuijpers
Journal:  J Thromb Haemost       Date:  2014-07-16       Impact factor: 5.824

8.  Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments.

Authors:  A Leyte; K Mertens; B Distel; R F Evers; M J De Keyzer-Nellen; M M Groenen-Van Dooren; J De Bruin; H Pannekoek; J A Van Mourik; M P Verbeet
Journal:  Biochem J       Date:  1989-10-01       Impact factor: 3.857

9.  Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method.

Authors:  Morten Nielsen; Claus Lundegaard; Ole Lund
Journal:  BMC Bioinformatics       Date:  2007-07-04       Impact factor: 3.169

10.  Limited promiscuity of HLA-DRB1 presented peptides derived of blood coagulation factor VIII.

Authors:  Simon D van Haren; Aleksandra Wroblewska; Eszter Herczenik; Paul H Kaijen; Aleksandra Ruminska; Anja ten Brinke; Alexander B Meijer; Jan Voorberg
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

View more
  9 in total

1.  The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.

Authors:  Bagirath Gangadharan; Mathieu Ing; Sandrine Delignat; Ivan Peyron; Maud Teyssandier; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

Review 2.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

3.  Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.

Authors:  Wojciech Jankowski; Yara Park; Joseph McGill; Eugene Maraskovsky; Marco Hofmann; Vincent P Diego; Bernadette W Luu; Tom E Howard; Roberta Kellerman; Nigel S Key; Zuben E Sauna
Journal:  Blood Adv       Date:  2019-05-14

4.  Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice.

Authors:  Qizhen Shi; Christopher V Carman; Yingyu Chen; Peter T Sage; Feng Xue; Xin M Liang; Gary E Gilbert
Journal:  Blood Adv       Date:  2020-05-26

5.  Complement C3 is a novel modulator of the anti-factor VIII immune response.

Authors:  Julie Rayes; Mathieu Ing; Sandrine Delignat; Ivan Peyron; Laurent Gilardin; Carl-Wilhelm Vogel; David C Fritzinger; Véronique Frémeaux-Bacchi; Srinivas V Kaveri; Lubka T Roumenina; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2017-11-16       Impact factor: 9.941

Review 6.  Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A.

Authors:  Yuanhua Cai; Qizhen Shi
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

Review 7.  Tolerating Factor VIII: Recent Progress.

Authors:  Sebastien Lacroix-Desmazes; Jan Voorberg; David Lillicrap; David W Scott; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

Review 8.  Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.

Authors:  Flora Peyvandi; Syna Miri; Isabella Garagiola
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

Review 9.  Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?

Authors:  Kenneth Lieuw
Journal:  J Blood Med       Date:  2017-06-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.